Across TCGA pan-cancer cohorts, SPRR4 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SPRR4 data layer compared with 21 for mass-spec protein and 2 for mass-spec protein.
The strongest signal is observed in acute myeloid leukemia (LAML), where higher SPRR4 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SPRR4 expression acts as an unfavorable survival marker.
LAML, LIHC, and ACC are the cancer types where SPRR4 Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.